Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis

Liver International

Volumn 28, Issue 8, 2008, Pages 1129-1135

  Lo Iacono, Oreste ^a   Rincón, Diego ^a   Hernando, Ana ^a   Ripoll, Cristina ^a   Catalina, Maria Vega ^a   Salcedo, Magdalena ^a   Clemente, Gerardo ^a   Gomez, Judith ^a   Nuñez, Oscar ^a   Matilla, Ana ^a   Bañares, Rafael ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

HVPG; Portal hypertension; sVCAM 1

Indexed keywords

SODIUM; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEMODYNAMICS; HEPATIC VEIN; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOASSAY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; PERIPHERAL VEIN; PORTAL VEIN BLOOD PRESSURE; PRESSURE GRADIENT; PROTEIN BLOOD LEVEL; SODIUM BLOOD LEVEL; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; SYSTEMIC VASCULAR RESISTANCE;

ADULT; FEMALE; HEMODYNAMICS; HEPATIC VEINS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPLANCHNIC CIRCULATION; VASCULAR CELL ADHESION MOLECULE-1; VENOUS PRESSURE;

EID: 48949104124     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01763.x     Document Type: Article

References (33)

1. Volpes R, Van den Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver inflammation. Hepatology 1990; 12: 59-65.
2. Pigott R, Dillon LP, Hemingway IH, et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-9.
3. Deem TL, Abdala-Valencia H, Cook-Mills JM. VCAM-1 activation of endothelial cell protein tyrosine phosphatase 1B. J Immunol 2007; 178: 3865-73.
4. Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000; 92: 1329-36.
5. Koch AE, Halloran MM, Haskell CJ, et al. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995; 376: 517-9.
6. Pigott R, Dillon LP, Hemingway IH, et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are presented in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-9.
7. Pirisi M, Fabris C, Falleti E, et al. Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases. Dis Markers 1996; 13: 11-7.
8. Lo Iacono O, Garcia-Monzon C, Almasio P, et al. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Aliment Pharmacol Ther 1998; 12: 1091-9.
9. Giron-Gonzalez JA, Martinez-Sierra C, Rodriguez-Ramos C, et al. Adhesion molecules as a prognostic marker of liver cirrhosis. Scand J Gastroenterol 2005; 40: 217-24.
10. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985; 248(Part 1): G618-25.
11. Sikuler E, Groszmann RJ. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol 1986; 250(Part 1): G205-12.
12. Abraldes JG, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006; 290: G980-7.
13. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
14. Child CG, Turcotte JC. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85.
15. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41: 32-9.
16. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336-43.
17. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-76.
18. Swan HJ, Ganz W, Forrester J, et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 1970; 283: 447-51.
19. Min JK, Kim YM, Kim SW, et al. TNF-related activation-induced cytokines enhances leukocyte adhesiveness: Induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells. J Immunol 2005; 175: 531-40.
20. Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996; 2: 992-7.
21. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-45.
22. Corpechot C, Barbu V, Wendum D, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002; 35: 1010-21.
23. Garcia-Monzon C, Sanchez-Madrid F, Garcia-Buey L, et al. Vascular adhesion molecule expression in viral chronic hepatitis: Evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231-41.
24. Medina J, Arroyo AG, Sanchez-Madrid F, et al. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004; 39: 1185-95.
25. Adams DH, Burra P, Hubscher SG, et al. Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease. Hepatology 1994; 19: 588-94.
26. Lim AG, Jazrawi RP, Levy JH, et al. Soluble E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in primary biliary cirrhosis. J Hepatol 1995; 22: 416-22.
27. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87: 1120-6.
28. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: A primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-7.
29. Fernandez M, Mejias M, Angermayr B, et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005; 43: 98-103.
30. Fernandez M, Vizzutti F, Garcia-Pagan JC, et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-94.
31. Desmet VJ, Roskams T. Cirrhosis reversal: A duel between dogma and myth. J Hepatol 2004; 40: 860-67.
32. Angeli P, Wong F, Watson H, et al. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006; 44: 1535-42.
33. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 2006; 44: 217-31.